Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis

J Am Acad Dermatol. 2011 Jul;65(1):224-6. doi: 10.1016/j.jaad.2009.11.034.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Absorptiometry, Photon
  • Administration, Oral
  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate
  • Mastocytosis, Systemic / complications
  • Mastocytosis, Systemic / drug therapy*
  • Mastocytosis, Systemic / pathology*
  • Middle Aged
  • Osteolysis / complications
  • Osteolysis / diagnostic imaging*
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate